Lung Cancer
Contact Info
-
+123+456-7890 -
sarahlee@prohealth.com
Appointment Schedules
- Monday 09.00-12.00
- Wednesday 15.00-18.00
- Friday 09.00-12.00
Ken ’O’Byrne
MBBS, FRACP, FRCPA, MD
Professor, Medical Oncology Princess Alexandra Hospital, Queensland University of Technology, Translational Research Institute (TRI) Australia
Degrees
-
University of California, San Francisco.
Medical degree
-
University of California, Los Angeles (UCLA) Medical Center.
Completed residency training in psychiatry
-
University of California, Berkeley.
Master of Public Health degree
Experiences
-
Worked in community mental health clinics, private practice, and academic medical centers.
-
Expertise in the treatment of mood disorders, anxiety disorders, and psychotic disorders.
-
Special interest in womens mental health and perinatal psychiatry.
-
Experience managing complex cases that involve both mental health and medical issues.
Awards/Achievements
-
Fellow of the American Psychiatric Association (FAPA).
-
Recognized for research contributions with grants from the National Institute of Mental Health (NIMH) and the American Foundation for Suicide Prevention.
Prof O’Byrne is the clinical lead for the ‘Cancer and Ageing Research Program’ at the Queensland University of Technology Translational Research Institute laboratories on the Princess Alexandra Hospital campus, his research includes biomarker identification in solid and liquid biopsies, drug resistance linked to cancer ‘stemness’ and genomic instability. His collaborations are global with ongoing projects on drug resistance, DNA repair and genomic instability, and whole genome and exome sequencing linked to groups in Europe and the US.
Prof O’Byrne, a clinical scientist translating science into patient care, has conducted translational ‘‘bench-to-bedside-and back-’again’ research over the past 25 years with a focus on solid epithelial tumours, in particular in thoracic malignancies. Prof O’Byrne has been involved in the design of and running phase I, II and III clinical trials encouraging the incorporation of biomarker studies, both prognostic and predictive. In 2013, Prof O’Byrne moved to Brisbane to take up a role as a member of the Australian Prostate Cancer Research Group establishing close links Professors Colleen Nelson and Judith Clements, and forging links with the prostate group in Vancouver, Canada.
He is the founder of the British Thoracic Oncology Group (BTOG), and founder member of the European thoracic oncology platform (ETOP), a member of the ESMO chest tumours faculty, is on the education and fellowship committees of the International Association for the Study of Lung Cancer (IASLC) and on the board of the Thoracic Alliance for Cancer Trials (TACT).,
He is co-chair of the advanced lung cancer sub-committee of the Australian Lung cancer Trials Group (ALTG), and a member of the Medical Oncology Group of Australasia (MOGA), Australian Genomics Health Alliance (AGHA) and Queensland Genomics Health Alliance (QGHA).
Prof O’Byrne has been involved in more than 200 Clinical Trials in his career including designing investigator-initiated, grant-funded Phase II and III studies. He has established collaborative studies and networks for biomarker detection and validation and has been involved in biomarker driven clinical trials including the LUX-Lung (Boehringer-Ingelheim), checkpoint immunotherapy (BMS, MSD) and the ETOP programs.
